Company
Business+Science
Our vision is to connect business and science to help each unique organization perform at its best. Our cloud-based tools help life sciences teams plan, monitor, analyze and ultimately manage performance across their R&D portfolios and corporations.
R&D Logic, Inc. is a privately held company whose management team has extensive industry experience. R&D Logic received its initial capital from Tenex Medical Investors group, institutional and other private investors.
Trusted by the industry
Our customer base includes life sciences companies at all stages of growth.
Two decades in business
Our leaders are industry veterans and the majority of our team members have been with us for over a decade..
Deep expertise
For biotech and life science professionals, the following statement won’t be a surprise: the life science industry is unique in its complexity.
Introducing our next-gen solution suite offering role-based graphical dashboards with Business Intelligence capabilities.
From R&D tax credits to the high risk of innovation to decades long product life cycles, the life science industry is like no other.
Time is money or any other commodity we care to translate it into, but the brutal truth is that it's the only resource we cannot recycle.
Your FP&A processes should sit on top of all your systems, creating an outlook that aligns with your past and present performance.
There's nothing really big about data unless you can convert it into information, then gather insight, and create knowledge.
High performance arises from fostering and leveraging the interdependence of roles in R&D-intensive environments..
Tracking time in R&D has two key dimensions: the time that’s going in and the time it takes to see results.
Experienced leadership
Wanda Ionescu
Chief Executive Officer
Wanda has extensive experience and in-depth technical expertise, having pioneered early internet technology that became one of the first web-based transactional systems for the R&D industry. Prior to founding R&D Logic, Wanda ran a premier consulting firm focused on architecting, developing and implementing business and scientific system solutions to address complex life sciences requirements. Wanda holds a MS in Computer Science and an MBA in Economic Cybernetics from Academy Of Sciences Bucharest, Romania.
Wanda Ionescu
Chief Executive Officer
full bio
Joyce Bellomo
Chief Financial Officer
Joyce brings decades of business experience and expertise to R&D Logic, having held leadership roles in finance at pharmaceutical companies and having developed and implemented multiple R&D-focused business strategies. Prior to R&D Logic, Joyce was the VP of Finance at Roche Bioscience and also held various finance positions at Syntex Pharmaceuticals. Joyce holds a MS in Business Administration and Marketing and a MBA in Finance from Santa Clara University.
Joyce Bellomo
Chief Financial Officer
full bio
Pierre Goldenstien
Vice President, Development
Pierre joins R&D Logic from W.I. Consulting where he served as lead architect and designer of key financial systems for companies such as Roche and Incyte Pharmaceuticals. Prior to W.I. Consulting, Pierre served as a consultant to Visa International. Since joining R&D Logic, Pierre has been responsible for architecting and developing the core R&D Logic application architecture. Pierre holds a MS in Biophysics from Physics University in Bucharest and a PhD in Biophysics and Molecular Biology from University of Paris.
Pierre Goldenstein
Vice President, Development
full bioOur news
March 2024
C4 Therapeutics is dedicated to delivering on the promise of targeted protein degradation (TPD) to create a new generation of medicines that transforms patients’ lives.
January 2024
Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions.
August 2023
Protego Biopharma focuses on the discovery and development of first- or best-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis.
August 2023
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
September 2022
With offices in Cambridge and London, UK, Sosei Heptares is focused on the discovery and early development of new medicines originating from their proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.
May 2022
With offices in Cambridge, MA, San Francisco, CA and Zug Switzerland CRISPR Therapeutics is focused on developing transformative gene-based medicines for serious human diseases.
April 2022
Located in Watertown, MA, Disc Medicines is committed to building a brighter future for patients. Using new discoveries and insights in hematology, they are advancing the frontiers of biology to create life-changing medicines.
March 2022
Located in Boston, MA, Ensoma is expanding the boundaries of genetic medicine – from rare monogenic illnesses to prevalent polygenic conditions such as autoimmune disease and cancer that affect millions around the world.
For earlier news, view our news archive.